Thursday, August 30, 2012
Collegium Pharmaceutical Inc., of Cumberland, R.I., said it started enrollment in a Phase III study of Oxycodone DETERx (COL-003), a tamper-resistant, extended-release version of oxycodone.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.